Katelyn Amos, PA
Emergency Medical Services · Kalamazoo, MINPI 1063994424
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $997 of the $1,152 with a category attached, or 86.6%. 17 manufacturers reported payments, led by GSK at 27.0% of the total. Reporting peaked in 2024 at $400 and has fallen 60.2% since, to $159 in 2025. Among emergency medical services clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$311
- Mylan Specialty L.p.$168
- Boehringer Ingelheim$122
- Regeneron Healthcare Solutions, Inc.$95
- AstraZeneca$94
- Grifols USA, LLC$78
- plus $285 from 11 others
What the payments were for
- Food & beverage$99787%
- Education$15413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 22 | $311 |
| Mylan Specialty L.p. | 10 | $168 |
| Boehringer Ingelheim | 6 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| AstraZeneca | 6 | $94 |
| Grifols USA, LLC | 4 | $78 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Electromed, Inc. | 4 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Pulmonx Corporation | 1 | $29 |
| Verona Pharma, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Sanofi | 1 | $17 |
| Amgen | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Genentech USA, Inc. | 2 | $9 |
How this compares
$1,152 in reported general payments places this provider in the 90th percentile of 180 emergency medical services providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 910 | $653,425 |
| Dupixent PenDupilumab | 53 | $216,108 |
| Pirfenidone | 14 | $127,463 |
| NucalaMepolizumab | 32 | $115,687 |
| Spiriva RespimatTiotropium Bromide | 166 | $106,908 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 118 | $81,531 |
| Dupixent SyringeDupilumab | 16 | $72,673 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 103 | $59,468 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 94 | $54,647 |
| Breo ElliptaFluticasone/Vilanterol | 85 | $41,821 |
| Advair HfaFluticasone Propion/Salmeterol | 74 | $32,551 |
| Incruse ElliptaUmeclidinium Bromide | 60 | $28,998 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 143 | $26,366 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 583 | $24,264 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 43 | $22,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $311 | $903,9421,207 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $122 | $183,977303 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $94 | $121,054228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 emergency medical services providers in Michigan.
Other emergency medical services in Kalamazoo
- Charles ZellerKalamazoo$454K
- Melissa TaylorGrand Rapids$60K
- Joshua WhiteLansing$26K
- Robert DunneDetroit$21K
- Brian GelbAlpena$4K
- Timothy ChildersReed City$4K
- Marc KrakowKalkaska$3K
- Roy ElrodDetroit$2K
- Julie JohnsonTraverse City$2K
- Matthew FlanniganGrand Rapids$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.